We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IMMP Immutep Ltd

0.01 (0.49%)
Last Updated: 12:09:35
Delayed by 15 minutes


Draw Mode:

Volume 49,068
Bid Price 2.06
Ask Price 2.07
News -
Company Name Stock Ticker Symbol Market Type
Immutep Ltd IMMP NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
0.01 0.49% 2.06 12:09:35
Open Price Low Price High Price Close Price Prev Close
2.05 2.035 2.11 2.05
Trades Volume VWAP Dollar Volume Avg Volume
326 49,068  2.08  102,024 -
Last Trade Time Type Quantity Stock Price Currency
12:09:35 500  2.06 USD

Immutep (IMMP) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


Immutep Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
368.06M 1.19B - 0 -39.9M -0.03 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Immutep

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No IMMP Message Board. Create One! See More Posts on IMMP Message Board See More Message Board Posts

IMMP Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year0.
3 Years0.
5 Years0.

Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's unique ability to stimulate or suppress the immune response. Immutep's lead clinical candidate, eftilagimod alpha ('efti'), is a soluble LAG-3 protein and first-in-class MHC Class II agonist that stimulates both innate and adaptive immunity to fight cancer.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |